Rasoul Shakiba1,2, Mohammad Ali Nilforoushzadeh3, Fataneh Hashem-Dabaghian1,2, Bagher Minaii Zangii4, Ali Ghobadi1,2, Laila Shirbeigi5, Jale Aliasl6, Mahdad Shakiba7, Roshanak Ghods1,2. 1. Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran. 2. School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran. 3. Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran. 4. Department of Histology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 5. Department of Traditional Medicine, School of Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran. 6. Traditional Medicine Clinical Trial Research Center, Shahed University, Tehran, Iran. 7. School of Pharmacy, International Campus, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
BACKGROUND: Acne is the most prevalent skin disease in the world and antibiotics as its standard treatments have limited and also adverse effects. Cedar (Ziziphus spina-christi) has medicinal properties like antibacterial activity and is used topically for treatment of some kinds of skin problems in Persian medicine. The aim of this study was to evaluation the efficacy of topical cedar solution of acne vulgaris. METHODS:Eighty patients aged between 15-45 years with mild to moderate acne vulgaris were conducted in this randomized, double blind trial. The participants were allocated to receive the topical cedar solution plus clindamycin 1% or topical placebo plus 1% clindamycin solution for six weeks. Patients were evaluated at the beginning of the study, second, sixth and eighth weeks after intervention for the acne severity index (ASI) and total acne lesions counting (TLC). Data was analyzed by SPSS software with Mann-Whitney U test. RESULTS: From 105 subjects 68 people completed the study (33 persons in cedar group and 35 persons in placebo group). The mean and standard deviation of the age was 26.1 ± 7.5 years and 22 subjects (32.4%) were male. TLC and ASI in the sixth and eighth weeks in cedar group were significantly less than in placebo group (p < 0.001). Topical cedar solution had no serious side effects. CONCLUSION: The topical cedar solution plus clindamycin 1% was more effective and safe than placebo plus 1% clindamycin for the treatment of acne vulgaris.
RCT Entities:
BACKGROUND: Acne is the most prevalent skin disease in the world and antibiotics as its standard treatments have limited and also adverse effects. Cedar (Ziziphus spina-christi) has medicinal properties like antibacterial activity and is used topically for treatment of some kinds of skin problems in Persian medicine. The aim of this study was to evaluation the efficacy of topical cedar solution of acne vulgaris. METHODS: Eighty patients aged between 15-45 years with mild to moderate acne vulgaris were conducted in this randomized, double blind trial. The participants were allocated to receive the topical cedar solution plus clindamycin 1% or topical placebo plus 1% clindamycin solution for six weeks. Patients were evaluated at the beginning of the study, second, sixth and eighth weeks after intervention for the acne severity index (ASI) and total acne lesions counting (TLC). Data was analyzed by SPSS software with Mann-Whitney U test. RESULTS: From 105 subjects 68 people completed the study (33 persons in cedar group and 35 persons in placebo group). The mean and standard deviation of the age was 26.1 ± 7.5 years and 22 subjects (32.4%) were male. TLC and ASI in the sixth and eighth weeks in cedar group were significantly less than in placebo group (p < 0.001). Topical cedar solution had no serious side effects. CONCLUSION: The topical cedar solution plus clindamycin 1% was more effective and safe than placebo plus 1% clindamycin for the treatment of acne vulgaris.
Entities:
Keywords:
Ziziphus spina-christi ; Acne; Persian medicine; cedar
Authors: Mahmoud Dogara Abdulrahman; Ali Muhammad Zakariya; Harmand A Hama; Saber W Hamad; Sawsan S Al-Rawi; Sarwan W Bradosty; Ahmad H Ibrahim Journal: Adv Pharmacol Pharm Sci Date: 2022-05-29